Abstract: The present invention includes compositions and methods comprising: a cancer antigen-specific chimeric antigen receptor cells, e.g., alpha-beta cell receptor T cells, gamma delta cell receptor T cells, induced pluripotent stem cells, hematopoietic stem cells, or natural killer (NK) cells or gamma delta cell receptor T cells, genetically engineered to express non-released IL-12, anchored IL-12, and/or cleavage-resistant IL-12 only, transfected with one or more costimulatory genes; and one or more immune modulators, regulated for safety, in an amount sufficient to eliminate the effect of at least one of myeloid derived suppressor cells (MDSC) or Tregs on the cells or CAR-T cells and eliminate cancer cells.

Abstract: A process for producing live, non-pathogenic, vaccines for the pathogens RNA turmor virus utilizes gene-altering technology to produce an altered genome which codes for the antigenic determinants of a pathogen, but has no genes coding for pathogenicity. The vaccine is the phenotypic expression of the altered genome. Specifically, an avian RNA tumor virus env gene is cloned into the non-pathogenic RNA virus RAV-O and the resulting recombinant product is replicated in host cells to provide a recombinant vaccine for the pathogen avian RNA tumor virus.